Upgrade to SI Premium - Free Trial

TRUFF (TRUFF)

0.03 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Latest Headlines

Rhelion unit signs USC supply deal for psilocybin drug candidate September 15, 2026 8:00 AM - StreetInsider Rhelion Life Sciences Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the University of Southern California for PEX010 in a Trial for Psilocybin-Assisted Mindfulness September 15, 2026 8:00 AM - StreetInsider Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Deliver Oral Comments at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs September 14, 2026 7:54 AM - StreetInsider Rhelion Life Sciences Announces Filament Health is Planning a Stability Program for IBEX011, Its Naturally Derived Ibogaine Drug Candidate September 10, 2026 7:57 AM - StreetInsider Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 to Australia for University of Melbourne Trial of Psilocybin-Assisted Physiotherapy in Functional Neurologic September 8, 2026 7:54 AM - StreetInsider Rhelion Life Sciences Confirms Further Delivery of Filament Health's PEX010 to Germany's First Psilocybin Compassionate Use Program September 3, 2026 7:40 AM - StreetInsider Rhelion Life Sciences Reports First Quarter 2027 Results August 31, 2026 8:41 AM - StreetInsider Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Issued New United States Patent, Extending the Broadest Natural Psilocybin Patent Estate August 27, 2026 8:26 AM - StreetInsider Filament Health ships psilocybin drug to UW cancer anxiety trial August 25, 2026 7:22 AM - StreetInsider Rhelion Life Sciences Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 for University of Washington Phase 2a Trial in Cancer-Related Anxiety and Depression August 25, 2026 7:22 AM - StreetInsider Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Letter of Intent with Darmiyan, Inc. to Explore Use of FDA De Novo Authorized BrainSee(R) AI Platform in Early Alzheimer's Disease August 20, 2026 7:41 AM - StreetInsider Rhelion Life Sciences Announces Appointment of Samiuddin Khaja as CFO August 19, 2026 8:16 AM - StreetInsider Rhelion unit to supply psilocybin for Parkinson's depression trial August 14, 2026 8:16 AM - StreetInsider Rhelion Life Sciences Signs Agreement with University Health Network for Randomized Clinical Trial of Psilocybin in Parkinson's Disease Depression August 14, 2026 8:16 AM - StreetInsider Rhelion Life Sciences Corp. Commences Trading Under New Name and Ticker Symbol RHEL on the CSE August 4, 2026 9:02 PM - StreetInsider Red Light Holland Reports Fiscal 2026 Audited Year-End Results and Provides Update on Rhelion Life Sciences July 29, 2026 7:54 AM - StreetInsider Red Light Holland Announces Corporate Rebrand to Rhelion Life Sciences Corp July 17, 2026 7:51 AM - StreetInsider Red Light Holland Announces New Filament Health PEX010 European Research Shipment July 16, 2026 8:04 AM - StreetInsider Red Light Holland Announces Filament Health's Largest-Ever Manufacturing Run of PEX010, the Standardized and Patented Natural Psilocybin Drug Candidate Trusted Across 80+ Studies Globally, Now Offerin July 8, 2026 8:02 AM - StreetInsider Filament Health to supply psilocybin drug for veterans PTSD study July 7, 2026 8:14 AM - StreetInsider Red Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Military Veterans PTSD Study at ARQ National Psychotrauma Centre July 7, 2026 8:14 AM - StreetInsider Red Light Holland reports preclinical coca extract results for post-GLP-1 weight management June 18, 2026 9:03 AM - StreetInsider Red Light Holland Reports Positive Preclinical Study Results for Coca in Weight Gain Prevention Post GLP-1 from Magdalena Biosciences, the Joint Venture Held Through Its Wholly Owned Subsidiary, Filam June 18, 2026 9:03 AM - StreetInsider Full Article List